Cabaletta Bio Advances Rare Disease Treatment with Pioneering Myositis Trial and Innovative Manufacturing Breakthrough
Cabaletta Bio has announced significant progress in its development of chimeric autoantibody receptor T cell (CAAR-T) therapies, marking a major milestone with the initiation of its first pivotal myositis trial…